Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.

[1]  G. Dusheiko,et al.  Current treatment of hepatitis B , 2007, Gut.

[2]  Y. Liaw,et al.  Chronic hepatitis B: treatment alert , 2006 .

[3]  I. Sheen,et al.  Emergence and takeover of precore‐stop mutant prior to exacerbation of e antigen‐negative chronic hepatitis B after withdrawal of lamivudine therapy , 2006, Journal of medical virology.

[4]  Ding-Shinn Chen,et al.  Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. , 2006, The Journal of infectious diseases.

[5]  Y. Liaw,et al.  Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[6]  A. Lok,et al.  Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B , 2004, Journal of viral hepatitis.

[7]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[8]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[9]  Y. Liaw,et al.  Short-Term Lamivudine Therapy in Patients with Chronic Hepatitis B , 2003, Intervirology.

[10]  C. Chu,et al.  Determinants for sustained HBeAg response to lamivudine therapy , 2003, Hepatology.

[11]  Y. Liaw.  Therapy of chronic hepatitis B: current challenges and opportunities , 2002, Journal of viral hepatitis.

[12]  M. Manns,et al.  Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.

[13]  M. Swain,et al.  Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[14]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[15]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[16]  C. Chu,et al.  Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.

[17]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[18]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[19]  J. Cullen,et al.  Lamivudine therapy of WHV-infected woodchucks. , 1998, Virology.

[20]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[21]  W. Mason,et al.  Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus , 1997, Journal of virology.

[22]  D. Tyrrell,et al.  Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.

[23]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[24]  F. Beland,et al.  Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3'-azido-2',3'-dideoxythymidine. , 1994, Cancer research.

[25]  V. Skalski,et al.  Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. , 1992, The Journal of biological chemistry.

[26]  R. Schinazi,et al.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  O. Yokosuka,et al.  Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. , 1991, The New England journal of medicine.

[28]  G. Fattovich,et al.  Natural history and prognostic factors for chronic hepatitis type B. , 1991, Gut.

[29]  C. Chu,et al.  Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. , 2008, Liver.

[30]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[31]  C. Chu,et al.  The development of cirrhosis in patients with chronic type B hepatitis: A prospective study , 1988, Hepatology.